Could Outpatient Cell Therapies Provide Way Out Of Bundled Payment Trap?
Cell Therapies Increasingly Developed With Outpatient Use In Mind
Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.
You may also be interested in...
Complete response rates for ALLO-501 and ALLO-501A look comparable so far to Gilead’s Yescarta, though longer follow-up is needed to judge if durability matches as well.
Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.
Breyanzi’s list price is $410,300. The CD19-targeting CAR-T therapy previously known as liso-cel has a lot of ground to make up following competitors Yescarta and Kymriah.